Items where authors include "Anthoney, A"

Article

McNamara, MG, Swain, J, Craig, Z et al. (21 more authors) (2023) NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma. eClinicalMedicine, 60. 102015. ISSN 2589-5370

Jones, R, Plummer, R, Moreno, V et al. (13 more authors) (2023) A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer. Clinical Cancer Research, 29 (2). pp. 331-340. ISSN 1078-0432

Kamposioras, K, Geraghty, J, Appleyard, J et al. (4 more authors) (2022) Pancreaticobiliary Malignancies in the Emergency Room: Management of Acute Complications and Oncological Emergencies. Journal of Gastrointestinal Cancer, 53 (4). pp. 1050-1065. ISSN 1941-6628

Samson, A orcid.org/0000-0002-3081-7850, West, EJ orcid.org/0000-0001-7449-120X, Carmichael, J et al. (27 more authors) (2022) Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients. Cancer Immunology Research, 10 (6). pp. 745-756. ISSN 2326-6066

Lamarca, A, Palmer, DH, Wasan, HS et al. (18 more authors) (2021) Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply. The Lancet Oncology, 22 (7). e288-e289. ISSN 1470-2045

Lamarca, A, Palmer, DH, Wasan, HS et al. (18 more authors) (2021) Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 22 (5). pp. 690-701. ISSN 1470-2045

Kamposioras, K, Mauri, D, Papadimitriou, K et al. (21 more authors) (2020) Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth. Frontiers in Oncology, 10. 575148. ISSN 2234-943X

Corrie, PG, Qian, W, Basu, B et al. (31 more authors) (2020) Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. British Journal of Cancer, 122. pp. 1760-1768. ISSN 0007-0920

de Bono, J, Lin, C-C, Chen, L-T et al. (20 more authors) (2020) Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. British Journal of Cancer, 122 (9). pp. 1324-1332. ISSN 0007-0920

Mauri, D, Kamposioras, K, Tzachanis, D et al. (18 more authors) (2020) Patient and family support in the era of fake e-medicine: food for thought from an international consensus panel. ESMO Open, 5 (2). e000696. ISSN 2059-7029

Jones, RP, Psarelli, E-E, Jackson, R et al. (38 more authors) (2019) Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. JAMA Surgery, 154 (11). pp. 1038-1048. ISSN 2168-6254

Papaxoinis, G, Kamposioras, K, Weaver, JMJ et al. (7 more authors) (2019) The Role of Continuing Perioperative Chemotherapy Post Surgery in Patients with Esophageal or Gastroesophageal Junction Adenocarcinoma: a Multicenter Cohort Study. Journal of Gastrointestinal Surgery, 23 (9). pp. 1729-1741. ISSN 1091-255X

Twelves, C, Anthoney, A, Savulsky, CI et al. (9 more authors) (2019) A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. British Journal of Cancer, 120 (6). pp. 579-586. ISSN 0007-0920

Schöffski, P, Wozniak, A, Stacchiotti, S et al. (20 more authors) (2019) Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’. Annals of Oncology, 30 (2). p. 344. ISSN 0923-7534

Kamposioras, K, Tsimplouli, C, Verbeke, C et al. (10 more authors) (2019) Silencing of caveolin-1 in fibroblasts as opposed to epithelial tumor cells results in increased tumor growth rate and chemoresistance in a human pancreatic cancer model. International Journal of Oncology, 54 (2). pp. 537-549. ISSN 1019-6439

Backen, AC, Lopes, A, Wasan, H et al. (16 more authors) (2018) Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. British Journal of Cancer, 119 (1). pp. 27-35. ISSN 0007-0920

Elander, NO, Aughton, K, Ghaneh, P et al. (25 more authors) (2018) Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. British Journal of Cancer, 118 (8). pp. 1084-1088. ISSN 0007-0920

Elander, NO, Aughton, K, Ghaneh, P et al. (25 more authors) (2018) Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. British Journal of Cancer, 118 (7). pp. 947-954. ISSN 0007-0920

Schöffski, P, Wozniak, A, Kasper, B et al. (23 more authors) (2018) Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’. Annals of Oncology, 29 (3). pp. 758-765. ISSN 0923-7534

Schöffski, P, Wozniak, A, Stacchiotti, S et al. (20 more authors) (2017) Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’. Annals of Oncology, 28 (12). pp. 3000-3008. ISSN 0923-7534

Hall, PS, Lord, SR, Collinson, M et al. (12 more authors) (2017) A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO). British Journal of Cancer, 116. pp. 472-478. ISSN 0007-0920

Conference or Workshop Item

Anthoney, A, Samson, A orcid.org/0000-0002-3081-7850, West, E et al. (14 more authors) (2018) Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity. In: 2018 ASCO Annual Meeting, 01-05 Jun 2018, Chicago, Il, USA.